Product Images Capecitabine

This is a prescription medication labeled as Capecitabine Tablets with a strength of 150mg. It comes in a bottle containing 60 tablets and has an NDC number of 62756-238-86. The manufacturer appears to be SUN, and there are additional codes, including PUB2050 and CUIDRUGS25780, that might be useful for identification purposes. The full labeling information is available for review.*

This appears to be the label of a bottle of Capecitabine Tablets, USP with NDC 62756-239-83. The bottle contains 30 tablets and is open for full labeling. There is also a code GUJ/DRUGS/25/789 and PJLB2053 present.*

The figure shows the Kaplan-Meier estimates of disease-free survival for two treatment groups - 5-FU+LEUCOVORIN and Capecitabine. The estimates are based on the survival data of the randomized population over 96 months since randomization. The text suggests that Capecitabine has been found to be not inferior to 5-FU/LV in terms of its efficacy.*

This is a graph (Figure 2) that shows the Kaplan-Meier Estimates of Overall Survival of two treatment groups (5-FU+LEUCOVORIN and CAPECITABINE) over time (measured in months). The survival rates are plotted on the y-axis from 0 to 1 with an increment of 0.1, and the months since randomization are plotted on the x-axis from 0 to 96. The data suggests that overall survival in the CAPECITABINE group was slightly better than in the 5-FU+LEUCOVORIN group.*

The text describes a Kaplan-Meier Curve for Overall Survival of Pooled Data from two studies. The graph shows estimated probability in X group with different treatment regimens. The first regimen is 5-FU-+Leucovorin (Mayo Regimen) while the second regimen is Capecitabine 1250 (mg/sqm twice daily) intermittent. The x-axis represents Time (Days) and the y-axis represents Estimated Probability. There are some unreadable characters in the text.*

This is a graph showing Kaplan-Meier estimates for time to disease progression comparing Capecitabine and Docetaxel vs Docetaxel alone. The estimated probability of disease progression is shown on the y-axis and time in days is shown on the x-axis. The treatment regimen for Capecitabine and Docetaxel is described in the text.*

The text describes a figure showing Kaplan-Meier Estimates of Survival for Capecitabine and Docetaxel vs Docetaxel. The figure includes estimated probabilities of survival with values ranging from 0.5 to 1.0. The treatments used were Docetaxel, Capecitabine, and a combination of both. The dosage for each treatment is also mentioned in the figure. The figure shows the estimated survival probability over time measured in days.*

This is a diagram of the metabolic pathway that capecitabine follows to be converted to 5-FU. It involves several enzymes, including carboxylesterase, cytidine deaminase, and dThdPase. The end product of the pathway is 5-FU.*